308 related articles for article (PubMed ID: 26351332)
1. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
[TBL] [Abstract][Full Text] [Related]
4. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
8. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
11. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J
Oncologist; 2014 Jul; 19(7):693-701. PubMed ID: 24869931
[TBL] [Abstract][Full Text] [Related]
15. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
[TBL] [Abstract][Full Text] [Related]
17. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
Dao BD; Ho H; Quintal LN
J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
19. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
[TBL] [Abstract][Full Text] [Related]
20. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
